At a glance
ClinicalIndex Comparison RecordN/ACompleted· 82,903 enrolled
Drug / intervention
extra-fine hydrofluoroalkane beclometasone dipropionate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective, Real-life Observational Evaluation of the Effectiveness and Cost-effectiveness of Extra-fine Hydrofluoroalkane (HFA) Beclometasone (BDP) Compared With Fluticasone Propionate (FP) in the Management of Asthma in a Representative Population in the United States (US)
In Brief
An observational study evaluating extra-fine hydrofluoroalkane beclometasone dipropionate and Fluticasone propionate for Asthma. Completed, enrolled 82,903 participants across 1 site.
Detailed Summary
This study will compare the absolute and relative effectiveness and cost-effectiveness of asthma management in patients in the USA on inhaled corticosteroid (ICS) maintenance therapy as HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone propionate (FP) pMDI. .
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom
Collaboratorsi3 Research, Teva Branded Pharmaceutical Products R&D, Inc.
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
Primary CompletionDec 2008
Study CompletionOct 2010
First PostedFeb 2011
TodayJul 2026
First PostedFeb 1, 2011
Enrollment StartJan 1, 2004
Primary CompletionDec 1, 2008
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.4 years ago
Interventions
extra-fine hydrofluoroalkane beclometasone dipropionatedrug
Fluticasone propionatedrug